A. Replacement therapy in adults and children in primary immunodeficiency syndromes such as:
• congenital agammaglobulinaemia and hypogammaglobulinaemia
• common variable immunodeficiency
• severe combined immunodeficiency and Wiskott-Aldrich syndrome
• IgG subclass deficiencies with recurrent infections

B. Replacement therapy in secondary immunodeficiencies (SID) in patients with severe or recurrent infections, ineffective antimicrobial treatment and either proven specific antibody failure (PSAF)* or serum IgG level of <4 g/l.
*PSAF=failure to mount at least a 2-fold rise in IgG antibody titre to pneumococcal polysaccharide and polypeptide antigen vaccines.

C. Immunomodulatory therapy:
• Hizentra is indicated for the treatment of patients with chronic inflammatory
demyelinating polyneuropathy (CIDP) as maintenance therapy to prevent relapse of
neuromuscular disability and impairment.